This is the authors' abstract. We don't add key points for this paper.
Dialysis facilities can make more money from administering epoetin than from dialysis and related routine services, which Medicare has reimbursed at a composite rate since 1983. Dr. Robert Steinbrook writes that in 2007, Congress may consider whether to eliminate financial incentives that may lead to the overuse of epoetin and other separately billable drugs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Robert Steinbrook (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: